Douglas Eby

Chief Executive Officer at Cambridge Science Corp.

Health Technology

Profile

Douglas Eby currently works at Cambridge Science Corp., as President, Chief Executive Officer & Director and Kyttaro Ltd., as Chief Executive Officer & Director.

Douglas Eby active positions

Companies	Position	Start
Cambridge Science Corp. Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA.	Chief Executive Officer	-
KYTTARO Ltd. KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby.	Chief Executive Officer	-

All active positions of Douglas Eby

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Douglas Eby's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Cambridge Science Corp. Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA.	Health Technology
KYTTARO Ltd. KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby.	Health Technology